Target intelligence / Profile preview

Coagulation factor XIII B chain (F13B) (F13B)

Target
F13B
Molecular classification
Complement control protein family (UniProt: P05160), Sushi domain-containing protein, Carrier protein, Glycoprotein
01

Overview

Coagulation factor XIII B chain (F13B) is a non-catalytic glycoprotein that serves as the essential carrier protein for the catalytic A-subunits in the blood, forming the heterotetrameric FXIII-A2B2 complex (UniProt: P05160). It is composed of ten Sushi domains, also known as complement control protein modules, and is synthesized primarily in the liver (NCBI Gene: 2165). The B-subunit's primary physiological role is to stabilize the A-subunit in circulation, preventing its premature degradation and extending its half-life from approximately 10 hours to 10 days (PMID: 28293116). It also acts as a regulatory molecule, modulating the rate of FXIII activation by thrombin and calcium during the final stages of the coagulation cascade. Genetic mutations in the F13B gene result in Factor XIII deficiency type I, a rare but severe bleeding disorder characterized by the depletion of both A and B subunits from the plasma (PMID: 15102357). Therapeutic management typically involves replacement therapy using plasma-derived FXIII concentrates containing the full A2B2 complex, such as Corifact, or recombinant A-subunit products like Catridecacog that associate with endogenous B-subunits upon administration (DrugBank: DB09014).

Other names
Factor XIII B subunitFibrin-stabilizing factor B subunitFXIII-BTransglutaminase B chainSushi domain-containing protein
02

Mechanism of action

The B-subunit acts as a carrier protein that stabilizes the catalytic A-subunit in plasma, protecting it from proteolytic degradation and regulating its activation by thrombin (PMID: 28293116).

03

Biological functions

Blood coagulation (NCBI Gene: 2165)Protein stabilizationRegulation of enzyme activationFibrin stabilization
04

Disease associations

Factor XIII deficiency (PMID: 15102357)Bleeding disorderHemorrhage
05

Safety considerations

Inhibitor formation (neutralizing antibodies) (DrugBank: DB09014)Thrombotic eventsHypersensitivity reactions
06

Interacting drugs

Coagulation factor XIII (human)

1 more in the full profile.

07

Biomarkers

Factor XIII-B antigen level (PMID: 15102357)Factor XIII activity (DrugBank: DB09014)

Beyond the preview

Go deeper on Coagulation factor XIII B chain (F13B) (F13B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coagulation factor XIII B chain (F13B) (F13B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call